Tempus AI, Inc. (NASDAQ:TEM) Director David R. Epstein Sells 990 Shares

Tempus AI, Inc. (NASDAQ:TEM) Director David R. Epstein sold 990 shares of the company’s stock in a transaction on Monday, March 17th. The shares were sold at an average price of $46.83, for a total value of $46,361.70. Following the completion of the transaction, the director now directly owns 26,284 shares in the company, valued at $1,230,879.72. This represents a 3.63 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Tempus AI Trading Up 5.0 %

Tempus AI stock traded up $2.29 during trading hours on Wednesday, hitting $48.03. The company had a trading volume of 11,624,616 shares, compared to its average volume of 5,018,028. Tempus AI, Inc. has a fifty-two week low of $22.89 and a fifty-two week high of $91.45. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17. The firm’s fifty day moving average is $55.86 and its 200-day moving average is $51.48.

Analyst Ratings Changes

TEM has been the topic of a number of recent analyst reports. Loop Capital cut their target price on Tempus AI from $57.00 to $52.00 and set a “buy” rating on the stock in a research report on Tuesday, January 14th. William Blair restated a “market perform” rating on shares of Tempus AI in a report on Tuesday, February 25th. Piper Sandler reduced their price objective on shares of Tempus AI from $70.00 to $55.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th. Needham & Company LLC lifted their target price on shares of Tempus AI from $56.00 to $70.00 and gave the stock a “buy” rating in a research report on Tuesday, February 25th. Finally, Guggenheim restated a “buy” rating on shares of Tempus AI in a report on Tuesday, February 25th. Six analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, Tempus AI currently has a consensus rating of “Moderate Buy” and an average target price of $61.18.

Hedge Funds Weigh In On Tempus AI

A number of hedge funds have recently modified their holdings of the stock. GSA Capital Partners LLP acquired a new stake in Tempus AI during the third quarter valued at $306,000. First Horizon Advisors Inc. acquired a new stake in shares of Tempus AI during the 3rd quarter valued at about $30,000. The Manufacturers Life Insurance Company grew its stake in shares of Tempus AI by 10.2% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 29,789 shares of the company’s stock valued at $1,686,000 after buying an additional 2,765 shares in the last quarter. Captrust Financial Advisors bought a new stake in shares of Tempus AI in the 3rd quarter valued at approximately $2,726,000. Finally, NEA Management Company LLC increased its holdings in Tempus AI by 17.8% in the third quarter. NEA Management Company LLC now owns 5,385,979 shares of the company’s stock worth $304,846,000 after buying an additional 813,169 shares during the last quarter. 24.22% of the stock is owned by institutional investors and hedge funds.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.